Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Firebrick Pharma Limited ( (AU:FRE) ) is now available.
Firebrick Pharma Limited has issued 22,402,222 ordinary fully paid shares, including 22,222,222 shares at $0.063 each and 180,000 shares from unlisted options at $0.025 each. This issuance, conducted without disclosure under the Corporations Act, signifies the company’s compliance with relevant financial regulations and supports its ongoing market expansion and product development efforts.
More about Firebrick Pharma Limited
Firebrick Pharma is a pharmaceutical innovator focused on developing and commercializing novel formulations and uses of povidone-iodine (PVP-I). The company has launched Nasodine® Nasal Spray in several markets, including the United States, Singapore, and Fiji & South Pacific, with plans to expand to the Philippines in 2026.
Average Trading Volume: 94,704
Technical Sentiment Signal: Buy
For a thorough assessment of FRE stock, go to TipRanks’ Stock Analysis page.